Enliven Therapeutics News

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BenzingaOct 31 11:37 ET

Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading

Dow JonesOct 31 07:22 ET · Ratings

JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36

Moomoo NewsOct 30 16:31 ET · Ratings

H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37

Moomoo NewsOct 1 09:31 ET · Ratings

Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate

TipRanksOct 1 08:35 ET · Ratings

TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating

Moomoo NewsSep 30 07:33 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)

TipRanksSep 30 01:50 ET · Ratings

LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsSep 29 09:31 ET · Ratings

Enliven Therapeutics Announces Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia; Reported Cumulative MMR Rate Of 44% (8/18) By 24 Weeks, With Stable Or Deepening Responses Between Weeks 12 And 24, Which Continues To...

BenzingaSep 28 09:42 ET

Express News | Enliven Therapeutics Inc - Elvn-001 Well-Tolerated With No Dose Reductions in 39 Patients

ReutersSep 28 09:35 ET

Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39

Moomoo NewsSep 23 22:32 ET · Ratings

Enliven Therapeutics Director Sells $28,458 in Company Stock

InvestingSep 18 16:22 ET

Express News | Enliven Therapeutics Announces Details Regarding Presentation Of Updated ELVN-001 Phase 1a Data As ESH-iCMLf 26th Annual John Goldman Conference On CML

BenzingaSep 18 16:06 ET

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

GlobeNewswireSep 18 16:05 ET

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

BenzingaSep 9 14:05 ET

H.C. Wainwright Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $37

Moomoo NewsSep 9 06:31 ET · Ratings

HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37

BenzingaSep 9 06:27 ET · Ratings

Enliven Therapeutics Analyst Ratings

BenzingaSep 9 06:24 ET · Ratings

Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Ascendis Pharma (ASND)

TipRanksSep 9 02:50 ET · Ratings

Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?

Yahoo FinanceSep 4 09:55 ET